Plant-derived natural products as leads for drug discovery

  • Li Pan
  • Esperanza J. Carcache de Blanco
  • A. Douglas Kinghorn


In this chapter, some successful drugs derived from plant secondary metabolites in their original or modified forms, and other substances, currently under clinical trial as drug candidates, as well as several additional compounds used as biochemical probes afforded from plants, will be described. A general description of the importance and perspective of plants in drug discovery will also be given.


Nuclear Magnetic Resonance Spectroscopy Betulinic Acid Shikimic Acid Tropane Alkaloid Nuclear Magnetic Resonance Probe 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kinghorn AD, Balandrin MF (Eds.) (1993) Human medicinal agents from plants, Symposium Series No. 534, American Chemical Society Books: Washington, DCGoogle Scholar
  2. 2.
    Dewick PM (2002) Medicinal natural products: a biosynthetic approach, 2nd edn. Wiley, New YorkGoogle Scholar
  3. 3.
    Newman DJ, Cragg GM, Snader KM (2003) Natural products as sources of new drugs over the period 1981–2002. J Nat Prod 66: 1022–1037PubMedGoogle Scholar
  4. 4.
    Samuelsson G (2004) Drugs of natural origin: a textbook of pharmacognosy, 5th Rev. edn. Swedish Pharmaceutical Press, StockholmGoogle Scholar
  5. 5.
    Balunas MJ, Kinghorn AD (2005) Drug discovery from medicinal plants. Life Sci 78: 431–441PubMedGoogle Scholar
  6. 6.
    Paterson I, Anderson EA (2005) The renaissance of natural products as drug candidates. Science 310: 451–453PubMedGoogle Scholar
  7. 7.
    Sneader W (2005) Drug discovery: a history. Wiley, ChichesterGoogle Scholar
  8. 8.
    The history of traditional Chinese medicine of more than 2000 years. Further information available at: (accessed November 2007)
  9. 9.
    Fabricant DS, Farnsworth NR (2001) The value of plants used in traditional medicine for drug discovery. Environ Health Perspect 109: 69–75PubMedGoogle Scholar
  10. 10.
    Sneader W (1996) Drug prototypes and their exploitation. Wiley, ChichesterGoogle Scholar
  11. 11.
    Bindseil KU, Jakupovic J, Wolf D, Lavayre J, Leboul J, van der Pyl D (2001) Pure compound libraries: a new perspective for natural product based drug discovery. Drug Discov Today 6: 840–847PubMedGoogle Scholar
  12. 12.
    Butler MS (2004) The role of natural product chemistry in drug discovery. J Nat Prod 67: 2141–2153PubMedGoogle Scholar
  13. 13.
    Vuorelaa P, Leinonenb M, Saikkuc P, Tammelaa P, Rauhad JP, Wennberge T, Vuorela H (2004) Natural products in the process of finding new drug candidates. Curr Med Chem 11: 1375–1389PubMedGoogle Scholar
  14. 14.
    Koehn FE, Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4: 206–220PubMedGoogle Scholar
  15. 15.
    Bajorath J (2002) Chemoinformatics methods for systematic comparison of molecules from natural and synthetic sources and design of hybrid libraries. J Comput Aided Mol Des 16: 431–439PubMedGoogle Scholar
  16. 16.
    Firn RD, Jones CG (2003) Natural products – a simple model to explain chemical diversity. Nat Prod Rep 20: 382–391PubMedGoogle Scholar
  17. 17.
    Lee ML, Schneider G (2001) Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. J Comb Chem 3: 284–289PubMedGoogle Scholar
  18. 18.
    Ganesan A (2004) Natural products as a hunting ground for combinatorial chemistry. Curr Opin Biotechnol 15: 584–590PubMedGoogle Scholar
  19. 19.
    Ortholand JY, Ganesan A (2004) Natural products and combinatorial chemistry: back to the future. Curr Opin Chem Biol 8: 271–280Google Scholar
  20. 20.
    Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461–477PubMedGoogle Scholar
  21. 21.
    Evans FJ (1991) Natural products as probes for new drug target identification. J Ethnopharmacol 32: 91–101PubMedGoogle Scholar
  22. 22.
    Williamson EM, Okpako DT, Evans FJ (1996) Pharmacological methods in phytotherapy research: Vol. 1. Selection, preparation and pharmacological evaluation of plant material. Wiley, New YorkGoogle Scholar
  23. 23.
    Newman DJ, Cragg GM, Holbeck S, Sausville EA (2002) Natural products and derivatives as leads to cell cycle pathway targets in cancer chemotherapy. Curr Cancer Drug Targets 2: 279–308PubMedGoogle Scholar
  24. 24.
    Koehn FE (2006) Therapeutic potential of natural product signal transduction agents. Curr Opin Biotechnol 17: 631–637PubMedGoogle Scholar
  25. 25.
    Kinghorn AD (2001) Pharmacognosy in the 21st century. J Pharm Pharmacol 53: 135–148Google Scholar
  26. 26.
    Jones WP, Chin YW, Kinghorn AD (2006) The role of pharmacognosy in modern medicine and pharmacy. Curr Drug Targets 7: 247–264PubMedGoogle Scholar
  27. 27.
    Hemscheidt T (2000) Tropane and related alkaloids. Topics Curr Chem 209: 175–206Google Scholar
  28. 28.
    Gadzikowska M, Grynkiewicz G (2002) Tropane alkaloids in pharmaceutical and phytochemical analysis. Acta Pol Pharm 59: 149–160PubMedGoogle Scholar
  29. 29.
    Rose JE, Behm, FM, Westman EC, Kukovich P (2006) Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicot Tobacco Res 8: 89–101Google Scholar
  30. 30.
    Clement JA, Yoder BJ, Kingston DGI (2004) Natural products as a source of CNS-active agents. Mini-Rev Med Chem 1: 183–208Google Scholar
  31. 31.
    Anekonda TS, Reddy PH (2005) Can herbs provide a new generation of drugs for treating Alzheimer’s disease? Brain Res Brain Res Rev 50: 361–376PubMedGoogle Scholar
  32. 32.
    Snyder SH, Pasternak GW (2003) Historical review: opioid receptors. Trends Pharmacol Sci 24: 198–205PubMedGoogle Scholar
  33. 33.
    Capsoni S, Giannotta S, Cattaneo A (2002) Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci USA 99: 12432–12437PubMedGoogle Scholar
  34. 34.
    Howes M-JR, Perry NSL, Houghton PJ (2003) Plants with traditional uses and activities, relevant to the management of Alzheimer’s disease and other cognitive disorders. Phytother Res 17: 1–18PubMedGoogle Scholar
  35. 35.
    Heinrich M, Teoh HL (2004) Galanthamine from snowdrop – the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge. J Ethnopharmacol 92: 147–162PubMedGoogle Scholar
  36. 36.
    Marco-Contelles J, Carreiras MdC, Rodriguez C, Villarroya M, Garcia AG (2006) Synthesis and pharmacology of galantamine. Chem Rev 106: 116–133PubMedGoogle Scholar
  37. 37.
    Frood A (2007) Scientists stir the pot for right to grow marijuana. Nat Med 13: 764PubMedGoogle Scholar
  38. 38.
    Lambert DM, Fowler CJ (2005) The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 48: 5059–5087PubMedGoogle Scholar
  39. 39.
    Barnes MP (2006) Sativex®: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Exp Opin Pharmacother 7: 607–615Google Scholar
  40. 40.
    Cook GC (2006) History of tropical medicine: William Ernest Cooke, FRCSI (1879–1967) and his Asian tour of 1929–1930. Acta Trop 100: 1–10PubMedGoogle Scholar
  41. 41.
    Bruneton J (1995) Pharmacognosy, phytochemistry, medicinal plants, 2nd edn. Lavoisier Publishing, New YorkGoogle Scholar
  42. 42.
    Li Y, Wu YL (1998) How Chinese scientists discovered qinghaosu (artemisinin) and developed its derivatives. What are the future perspectives? Med Trop (Mars.) 58: 9–12Google Scholar
  43. 43.
    Golenser J, Waknine JH, Krugliak M, Hunt NH, Grau GE (2006) Current perspectives on the mechanism of action of artemisinins. Int J Parasitol 36: 1427–1441PubMedGoogle Scholar
  44. 44.
    Kerr C (2006) Companies agree to withdraw artemisinin monotherapy. Lancet Infect Dis 6: 397Google Scholar
  45. 45.
    Buchtel L, Ventura HO (2006) Lunar Society and the discovery of digitalis. J La State Med Soc 158: 26–30PubMedGoogle Scholar
  46. 46.
    Warren B (2005) Digitalis purpurea. Am J Cardiol 95: 544PubMedGoogle Scholar
  47. 47.
    Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93: 2325–2327PubMedGoogle Scholar
  48. 48.
    Cragg GM, Newman DJ (2004) A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. J Nat Prod 67: 232–244PubMedGoogle Scholar
  49. 49.
    Kingston DGI, Newman DJ (2007) Taxoids: cancer-fighting compounds from nature. Curr Opin Drug Discov Dev 10: 130–144Google Scholar
  50. 50.
    Lee JC, Harrison D, Timasheff SN (1975) Interaction of vinblastine with calf brain microtubule protein. J Biol Chem 250: 9276–9282PubMedGoogle Scholar
  51. 51.
    Van Der Heijden, R Jacobs DI, Snoeijer W, Hallard D, Verpoorte R (2004) The Catharanthus alkaloids: pharmacognosy and biotechnology. Curr Med Chem 11: 607–628Google Scholar
  52. 52.
    Cragg GM, Newman DJ (2005) Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72–79PubMedGoogle Scholar
  53. 53.
    van Agtmael MA, Eggelte TA, van Boxtel CJ (1999) Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication. Trends Pharmacol Sci 20: 199–205PubMedGoogle Scholar
  54. 54.
    O’Neill PM (2005) The therapeutic potential of semi-synthetic artemisinin and synthetic endoperoxide antimalarial agents. Expert Opin Investig Drugs 14: 1117–1128PubMedGoogle Scholar
  55. 55.
    Hallett RL, Sutherland CJ, Alexander N, Ord R, Jawara M, Drakeley CJ, Pinder M, Walraven G, Targett GA, Alloueche A (2004) Combination therapy counteracts the enhanced transmission of drug-resistant malaria parasites to mosquitoes. Antimicrob Agents Chemother 48: 3940–3943PubMedGoogle Scholar
  56. 56.
    Facts on acts (Artemisinin-based combination therapies). Further information available at: (accessed November 2007)
  57. 57.
    Kingston DGI (2000) Recent advances in the chemistry of taxol. J Nat Prod 63: 726–734PubMedGoogle Scholar
  58. 58.
    Nicolaou KC, Yang Z, Liu JJ, Ueno H, Nantermet PG, Guy RK, Claiborne CF, Renaud J, Couladouros EA, Paulvannan K, Sorensen EJ (1994) Total synthesis of taxol. Nature 367: 630–634PubMedGoogle Scholar
  59. 59.
    Holton RA, Somoza C, Kim HB, Liang F, Biediger RJ, Boatman PD, Shindo M, Smith CC, Kim SC, Nadizadeh H, Suzuki Y, Tao CL, Vu P, Tang S, Zhang P, Murthi KK, Gentile LN, Liu JH (1994) First total synthesis of taxol. 1. Functionalization of the B ring. J Am Chem Soc 116: 1597–1598Google Scholar
  60. 60.
    Holton RA, Somoza C, Kim HB, Liang F, Biediger RJ, Boatman PD, Shindo M, Smith CC, Kim SC, Nadizadeh H, Suzuki Y, Tao CL, Vu P, Tang S, Zhang P, Murthi KK, Gentile LN, Liu JH (1994) First total synthesis of taxol. 2. Completion of the C and D rings. J Am Chem Soc 116: 1599–1600Google Scholar
  61. 61.
    Kingston DGI (2006) Taxol and its analogs. In: Cragg GM, Kingston DGI, Newman DJ (eds) Anticancer Agents from Natural Products. Taylor & Francis, Boca Raton, FL, pp 89–122Google Scholar
  62. 62.
    Guénard D, Guéritte-Voegelein F, Potier P (1993) Taxol and Taxotere: discovery, chemistry and structure-activity relationships. Acc Chem Res 26: 160–167Google Scholar
  63. 63.
    De Clercq E (2006) Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 5: 1015–1025PubMedGoogle Scholar
  64. 64.
    Laver G (2006) Antiviral drugs for influenza: Tamifluâ past, present and future. Future Virol 1: 577–586Google Scholar
  65. 65.
    Payne R, Edmonds M (2005) Isolation of shikimic acid from star aniseed. J Chem Ed 82: 599–600Google Scholar
  66. 66.
    Poon T, Enrich L, Mohadjer A (2007) Quantitative analysis and isolation of shikimic acid from Liquidambar styraciflua. Abstracts of Papers, 233rd American Chemical Society National Meeting, Chicago, IL, March 25–29Google Scholar
  67. 67.
    Krämer M, Bongaerts J, Bovenberg R, Kremer S, Müller U, Orf S, Wubbolts M, Raeven L (2003) Metabolic engineering for microbial production of shikimic acid. Metab Eng 5: 277–283PubMedGoogle Scholar
  68. 68.
    Yeung YY, Hong S, Corey EJ (2006) A short enantioselective pathway for the synthesis of the anti-influenza neuramidase inhibitor oseltamivir from 1,3-butadiene and acrylic acid. J Am Chem Soc 128: 6310–6311PubMedGoogle Scholar
  69. 69.
    Duke SO, Dayan FE, Romagni JG, Rimando AM (2000) Natural products as sources of herbicides: current status and future trends. Weed Res 40: 99–111Google Scholar
  70. 70.
    McKiernan PJ (2006) Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs 66: 743–750PubMedGoogle Scholar
  71. 71.
    Anonymous (2007) Nitisinone: new drug. Type 1 tyrosinemia: an effective drug. Prescrire Int 16: 56–58Google Scholar
  72. 72.
    Booth M (1984) Opium: a history. St. Martin’s Press, New YorkGoogle Scholar
  73. 73.
    US Food and Drug Administration. CDER new molecular entity (NME) drugs and new biologic approvals in calendar year 2004. Further information available at: (accessed November 2007)
  74. 74.
    Ridgway D (2004) Analgesics for acute pain: meeting the United States Food and Drug Administration’s requirements for proof of efficacy. Clin J Pain 20: 123–132PubMedGoogle Scholar
  75. 75.
    van Dorp ELA, Yassen A, Dahan A (2007) Naloxone treatment in opioid addiction: the risks and benefits. Expert Opin Drug Saf 6: 125–132PubMedGoogle Scholar
  76. 76.
    Volpicelli JR, Fenton M (2006) Sustained-release naltrexone formulations for the treatment of alcohol and opioid dependence. Future Neurol 1: 389–398Google Scholar
  77. 77.
    Paul IM, Shaffer ML, Yoder KE, Sturgis SA, Baker MS, Berlin CM Jr (2004) Dose-response relationship with increasing doses of dextromethorphan for children with cough. Clin Ther 26: 1508–1514PubMedGoogle Scholar
  78. 78.
    Canel C, Moraes RM, Dayan FE, Ferreira D (2000) Molecules of interest: podophyllotoxin. Phytochemistry 54: 115–120PubMedGoogle Scholar
  79. 79.
    Srivastava V, Negi AS, Kumar JK, Gupta MM, Khanuja SPS (2005) Plant-based anticancer molecules: a chemical and biological profile of some important leads. Bioorg Med Chem 21: 5892–5908Google Scholar
  80. 80.
    Martincic D, Hande KR (2005) Topoisomerase II inhibitors. Cancer Chemother Biol Response Modif 22: 101–121PubMedGoogle Scholar
  81. 81.
    Grynkiewicz G, Achmatowicz O, Pucko W (2000) Bioactive isoflavone – genistein. Synthesis and prospective applications. Herba Pol 46: 151–160Google Scholar
  82. 82.
    Molokanova E, Savchenko A, Kramer RH (2000) Interactions of cyclic nucleotide-gated channel subunits and protein tyrosine kinase probed with genistein. J Gen Physiol 115: 685–696PubMedGoogle Scholar
  83. 83.
    Ravindranath MH, Muthugounder S, Presser N, Viswanathan S (2004) Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol 546: 121–165PubMedGoogle Scholar
  84. 84.
    Bhat SV (1993) Forskolin and congeners. Prog Chem Org Nat Prod 62: 1–74Google Scholar
  85. 85.
    de Souza NJ, Dohadwalla AN, Reden J (1983) Forskolin: a labdane diterpenoid with antihypertensive, positive inotropic, platelet aggregation inhibitory, and adenylate cyclase activating properties. Med Res Rev 3: 201–219PubMedGoogle Scholar
  86. 86.
    Tesmer JJ, Sprang SR (1998) The structure, catalytic mechanism and regulation of adenylyl cyclase. Curr Opin Struct Biol 8: 713–719PubMedGoogle Scholar
  87. 87.
    Gilani AUH (1998) Novel developments from natural products in cardiovascular research. Phytother Res 12: S66-S69Google Scholar
  88. 88.
    Iwatsubo K, Okumura S, Ishikawa Y (2006) Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling. Endocr Metab Immune Disord Drug Targets 6: 239–247PubMedGoogle Scholar
  89. 89.
    Formica JV, Regelson W (1995) Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol 12: 1061–1080Google Scholar
  90. 90.
    Moskaug JO, Carlsen H, Myhrstad M, Blomhoff R (2004) Molecular imaging of the biological effects of quercetin and quercetin-rich foods. Mech Ageing Dev 125: 315–324PubMedGoogle Scholar
  91. 91.
    Lakhanpal P, Rai DK (2007) Quercetin: a versatile flavonoid. Internet J Med Update 2(2): Further information available at: (accessed December 2007)
  92. 92.
    Rawel HM, Meidtner K, Kroll J (2005) Binding of selected phenolic compounds to proteins. J Agric Food Chem 53: 4228–4235PubMedGoogle Scholar
  93. 93.
    Marinic M, Piantanida I, Rusak G, Zinic M (2006) Interactions of quercetin and its lanthane complex with double stranded DNA/RNA and single stranded RNA: Spectrophotometric sensing of poly G. J Inorg Biochem 100: 288–298PubMedGoogle Scholar
  94. 94.
    Nifli AP, Theodoropoulos PA, Munier S, Castagnino C, Roussakis E, Katerinopoulos HE, Vercauteren J, Castanas E (2007) Quercetin exhibits a specific fluorescence in cellular milieu: a valuable tool for the study of its intracellular distribution. J Agric Food Chem 55: 2873–2878PubMedGoogle Scholar
  95. 95.
    Kazanietz MG, Caloca MJ, Eroles P, Fujii T, Garcia-Bermejo ML, Reilly M, Wang H (2000) Pharmacology of the receptors for the phorbol ester tumor promoters: multiple receptors with different biochemical properties. Biochem Pharmacol 60: 1417–1424PubMedGoogle Scholar
  96. 96.
    Gunjan G, Harinder PSM, George F, Klaus B (2007) Phorbol esters: structure, biological activity, and toxicity in animals. Int J Toxicol 26: 279–288Google Scholar
  97. 97.
    Montesano R, Orci L (1985) Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell 42: 469–477PubMedGoogle Scholar
  98. 98.
    Lee JC, Harrison D, Timasheff SN (1975) Interaction of vinblastine with calf brain microtubule protein. J Biol Chem 250: 9276–9282PubMedGoogle Scholar
  99. 99.
    Cortese F, Bhattacharyya B, Wolff J (1977) Podophyllotoxin as a probe for the colchicine binding site of tubulin. J Biol Chem 252: 1134–1140PubMedGoogle Scholar
  100. 100.
    Horwitz SB, Parness J, Schiff PB, Manfredi JJ (1982) Taxol: a new probe for studying the structure and function of microtubules. Cold Spring Harb Symp Quant Biol 46: 219–226PubMedGoogle Scholar
  101. 101.
    Hearn BR, Shaw SJ, Myles DC (2006) Microtubule targeting agents. Comp Med Chem II 7: 81–110Google Scholar
  102. 102.
    Lampson MA, Kapoor TM (2007) Using small molecules to unravel biological mechanisms. Chem Biol 1: 71–94Google Scholar
  103. 103.
    Szolcsanyi J, Szallasi A, Szallasi Z, Joo F, Blumberg PM (1990) Resiniferatoxin: an ultrapotent selective modulator of capsaicin-sensitive primary afferent neurons. J Pharmacol Exp Ther 255: 923–928PubMedGoogle Scholar
  104. 104.
    Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389: 816–824PubMedGoogle Scholar
  105. 105.
    Watson CP, Evans RJ, Watt VR (1988) Post-herpetic neuralgia and topical capsaicin. Pain 33: 333–340PubMedGoogle Scholar
  106. 106.
    Anesiva, Inc. Further information available at: (accessed November 2007)
  107. 107.
    Butler MS (2005) Natural products to drugs: natural product compounds in clinical trials. Nat Prod Rep 22: 162–195PubMedGoogle Scholar
  108. 108.
    Chin YW, Balunas MJ, Chai HB, Kinghorn AD (2006) Drug discovery from natural sources. AAPS J 8: E239–253PubMedGoogle Scholar
  109. 109.
    Corson TW, Crews CM (2007) Molecular understanding and modern application of traditional medicines: Triumphs and trials. Cell 130: 769–774PubMedGoogle Scholar
  110. 110.
    Tanaka O, Nagai M, Shibata S (1966) Chemical studies on the oriental plant drugs. XVI. The stereochemistry of protopanaxadiol, a genuine sapogenin of ginseng. Chem Pharm Bull 14: 1150–1156PubMedGoogle Scholar
  111. 111.
    Popovich DG, Kitts DD (2002) Structure-function relationship exists for ginsenosides in reducing cell proliferation and inducing apoptosis in the human leukemia (THP-1) cell line. Arch Biochem Biophys 406: 1–8PubMedGoogle Scholar
  112. 112.
    Li G, Wang ZH, Sun YX, Liu K, Wang Z (2006) Ginsenoside 20(S)-protopanaxadiol inhibits the proliferation and invasion of human fibrosarcoma HT1080 cells. Basic Clin Pharmacol Toxicol 98: 588–592PubMedGoogle Scholar
  113. 113.
    Liu GY, Bu X, Yan H, Jia WWG (2007) 20S-Protopanaxadiol-induced programmed cell death in glioma cells through caspase-dependent and -independent pathways. J Nat Prod 70: 259–265PubMedGoogle Scholar
  114. 114.
    PanaGin Pharmaceuticals, Inc. Further information available at: (accessed November 2007)
  115. 115.
    Smith CR Jr, Powell RG, Mikolajczak KL (1976) The genus Cephalotaxus: source of homoharringtonine and related anticancer alkaloids. Cancer Treat Rep 60: 1157–1170PubMedGoogle Scholar
  116. 116.
    Luo, CY, Tang JY, Wang YP (2004) Homohar-ringtonine: a new treatment option for myeloid leukemia. Hematology 9: 259–270PubMedGoogle Scholar
  117. 117.
    Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O’Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J (2007) Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109: 248–255PubMedGoogle Scholar
  118. 118.
    The Rocky Mountain blood and marrow transplant program (RMBMTP), Initial patients treated in multinational phase 2/3 study of ceflatonin 09–20–2006. Further information available at: (accessed January 2008)
  119. 119.
    Yeung H-C (1985) Handbook of Chinese herbs and formulas. Institute of Chinese Medicine, Los Angeles, CAGoogle Scholar
  120. 120.
    Further information for oxymatrine available at: (accessed November 2007)
  121. 121.
    Li J, Li C, Zeng M (1998) Preliminary study on therapeutic effect of oxymatrine in treating patients with chronic hepatitis C. Chin J Integr Tradit West Med 18: 227–229Google Scholar
  122. 122.
    Xiang XX, Wang GJ, Cai X, LI YL (2002) Effect of oxymatrine on murine fulminant hepatitis and hepatocyte apoptosis. Chin Med J 115: 593–596PubMedGoogle Scholar
  123. 123.
    Mao YM, Zeng MD, Lu LG, Wan MB, Li CZ, Chen CW, Fu QC, Wang JY, She WM, Cai X, Ye J, Zhou XQ, Wang H, Wu SM, Tang MF, Zhu JS, Chen WX, Zhang HQ (2004) Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: a randomized, double blind, placebo-controlled, multicenter clinical study. World J Gastroenterol 10: 3269–3273PubMedGoogle Scholar
  124. 124.
    Constantinou AI, Husband A (2002) Phenoxodiol [2H-1-benzopyran-7-ol, 3-(4-hydroxyphenyl)], a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Anticancer Res 22: 2581–2585PubMedGoogle Scholar
  125. 125.
    Choueiri TK, Wesolowski R, Mekhail TM (2006) Phenoxodiol: isoflavone analog with antineoplastic activity. Curr Oncol Rep 8: 104–107PubMedGoogle Scholar
  126. 126.
    Schweigerer L, Christeleit K, Fleischmann G, Adlercreutz H, Wahala K, Hase T, Schwab M, Ludwig R, Fotsis T (1992) Identification in human urine of a natural growth inhibitor for cells derived from solid paediatric tumours. Eur J Clin Invest 22: 260–264PubMedGoogle Scholar
  127. 127.
    Mor G, Fu HH, Alvero AB (2006) Phenoxodiol, a novel approach for the treatment of ovarian cancer. Curr Opin Investig Drugs 7: 542–548PubMedGoogle Scholar
  128. 128.
    Liu JS, Zhu YL, Yu CM, Zhou YZ, Han YY, Wu FW, Qi BF (1986) The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity. Can J Chem 64: 837–839Google Scholar
  129. 129.
    Jiang HL, Luo XM, Bai DL (2003) Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional Chinese medicine origin for the treatment of Alzheimer’s disease. Curr Med Chem 10: 2231–2252PubMedGoogle Scholar
  130. 130.
    Ma XQ, Tan CH, Zhu DY, Gang DR, Xiao PG (2007) Huperzine A from Huperzia species – an ethnopharmacological review. J Ethnopharmacol 113: 15–34PubMedGoogle Scholar
  131. 131.
    US National Institutes of Health. Huperzine A in Alzheimer’s disease. Further information available at: (accessed November 2007)
  132. 132.
    Debiopharm. Debio-9902 (formerly ZT-1) A novel treatment for Alzheimer’s disease. Further information available at: (accessed November 2007)
  133. 133.
    Alakurtti S, Mäkelä T, Koskimies S, Yli-Kauhaluoma J (2006) Pharmacological properties of the ubiquitous natural product betulin. Eur J Pharm Sci 29: 1–13PubMedGoogle Scholar
  134. 134.
    Cichewicz RH, Kouzi SA (2004) Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med Res Rev 24: 90–114PubMedGoogle Scholar
  135. 135.
    Liby K, Honda T, Williams CR, Risingsong R, Royce DB, Suh N, Dinkova-Kostova AT, Stephenson KK, Talalay P, Sundararajan C, Gribble GW, Sporn MB (2007) Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities. Mol Cancer Ther 6: 2113–2119PubMedGoogle Scholar
  136. 136.
    US National Institutes of Health. Evaluation of 20% betulinic acid ointment for treatment of dysplastic nevi (moderate to severe dysplasia). Further information available at: (accessed November 2007)
  137. 137.
    Temesgen Z, Feinberg JE (2006) Drug evaluation: bevirimat-HIV gag protein and viral maturation inhibitor. Curr Opin Invest Drugs 7: 759–765Google Scholar
  138. 138.
    Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian Ferri, Nagashima K, Li F, Salzwedel K, Sakalian M, Wild CT, Freed EO (2006) In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (bevirimat). J Virol 80: 10957–10971PubMedGoogle Scholar
  139. 139.
    Martin DE, Blum R, Wilton J, Doto J, Galbraith H, Burgess GL, Smith PC, Ballow C (2007) Safety and pharmacokinetics of bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrob Agents Chemother 51: 3063–3066PubMedGoogle Scholar
  140. 140.
    Martin DE, Blum R, Doto J, Galbraith H, Ballow C (2007) Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers. Clin Pharmacokinet 46: 589–598PubMedGoogle Scholar
  141. 141.
    Young SL, Chaplin DJ (2004) Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs 13: 1171–1182PubMedGoogle Scholar
  142. 142.
    Siemann DW, Chaplin DJ, Horsman MR (2004) Vascular-targeting therapies for treatment of malignant disease. Cancer 100: 2491–2499PubMedGoogle Scholar
  143. 143.
    OXiGENE, Inc: Press releases June 5, 2006 and September 12, 2006. Further information available at: (accessed November 2007)
  144. 144.
    Singh S (2007) From exotic spice to modern drug? Cell 130: 765–768PubMedGoogle Scholar
  145. 145.
    Aggarwal BB, Sundaram C, Malani N, Ichikawa H (2007) Curcumin: the Indian solid gold. Adv Exp Med Biol 595: 1–75PubMedGoogle Scholar
  146. 146.
    Cordell GA, Colvard MD (2005) Some thoughts on the future of ethnopharmacology. J Ethnopharmacol 100: 5–14PubMedGoogle Scholar
  147. 147.
    Bringmann G, Messer K, Wohlfarth M, Kraus J, Dumbuya K, Rückert M (1999) HPLC-CD on-line coupling in combination with HPLC-NMR and HPLC-MS/MS for the determination of the full absolute stereostructure of new metabolites in plant extracts. Anal Chem 71: 2678–2686Google Scholar
  148. 148.
    Niessen WMA, Lin J, Bondoux GC (2002) Developing strategies for isolation of minor impurities with mass spectrometry-directed fractionation. J Chromatogr A 970: 131–140PubMedGoogle Scholar
  149. 149.
    Wolfender JL, Ndjoko K, Hostettmann K (2003) Liquid chromatography with ultraviolet absorbance-mass spectrometric detection and with nuclear magnetic resonance spectrometry: a powerful combination for the on-line structural investigation of plant metabolites. J Chromatogr A 1000: 437–455PubMedGoogle Scholar
  150. 150.
    Reynolds WF, Enriquez RG (2002) Choosing the best pulse sequences, acquisition. parameters, postacquisition processing strategies and probes for natural products structure elucidation by NMR spectroscopy. J Nat Prod 65: 221–244PubMedGoogle Scholar
  151. 151.
    Lewis RJ, Bernstein MA, Duncan SJ, Sleigh CJ (2005) A comparison of capillary-scale LC-NMR with alternative techniques: spectroscopic and practical considerations. Magn Reson Chem 43: 783–789PubMedGoogle Scholar
  152. 152.
    Corcoran O, Spraul M (2003) LC-NMR-MS in drug discovery. Drug Discov Today 8: 624–631PubMedGoogle Scholar
  153. 153.
    Martin GE (2005) Small-volume and high-sensitivity NMR probes. Annu Rep NMR Spectrosc 56: 1–96Google Scholar
  154. 154.
    Anonymous (2007) Assay development. Nat Rev Drug Disc 6: 681Google Scholar
  155. 155.
    Potterat O, Hamburger M (2006). Natural products in drug discovery - concepts and approaches for tracking bioactivity. Curr Org Chem 10: 899–920Google Scholar
  156. 156.
    Roddy TP, Horvath CR, Stout SJ, Kenney KL, Ho P-I, Zhang J-H, Vickers C, Kaushik V, Hubbard B, Wang YK (2007) Mass spectrometric techniques for label-free high-throughput screening in drug discovery. Anal Chem 79: 8207–8213PubMedGoogle Scholar
  157. 157.
    Manchester KL (1995) Louis Pasteur (1822–1895) – chance and the prepared mind. Trends Biotechnol 13: 511–515PubMedGoogle Scholar
  158. 158.
    Turner MK (1995) Biocatalysis in organic chemistry (Part II): present and future. Trends Biotechnol 13: 253–258Google Scholar
  159. 159.
    Rao SR, Ravishankar GA (2002) Plant cell cultures: chemical factories of secondary metabolites. Biotechnol Adv 20: 101–153PubMedGoogle Scholar
  160. 160.
    Fischbach MA, Walsh CT (2006) Biochemistry: directing biosynthesis. Science 314: 603–605PubMedGoogle Scholar
  161. 161.
    Ritter SK (2004) Green innovations. Chem Eng News 12: 25–30Google Scholar
  162. 162.
    Rokem JS, Tal B, Goldberg I (1985) Methods for increasing diosgenin production by Dioscorea cells in suspension cultures. J Nat Prod 48: 210–220Google Scholar
  163. 163.
    van Der Heijden R, Jacobs DI, Snoeijer W, Hallard D, Verpoorte R (2004) Catharanthus alkaloids: pharmacognosy and biotechnology. Curr Med Chem 11: 607–628Google Scholar
  164. 164.
    Moyano E, Osuna L, Bonfill M, Cusido RM, Palazon J, Tortoriello J, Pinol MT (2005) Bioproduction of triterpenes on plant cultures of Panax ginseng and Galphimia glauca. In: Pandalai SG (ed) Recent Research Developments in Plant Science, Vol. 3. Research Signpost, Kerala, India, p 195Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Li Pan
    • 1
  • Esperanza J. Carcache de Blanco
    • 1
  • A. Douglas Kinghorn
    • 1
  1. 1.Division of Medicinal Chemistry and PharmacognosyCollege of Pharmacy, The Ohio State UniversityColumbusUSA

Personalised recommendations